|
Category: pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Physical Properties:
| Appearance: | white crystalline powder (est) |
| Assay: | 95.00 to 100.00 %
|
| Food Chemicals Codex Listed: | No |
| Melting Point: | 257.00 °C. @ 760.00 mm Hg
|
| Boiling Point: | 676.27 °C. @ 760.00 mm Hg (est)
|
| Vapor Pressure: | 6.000000 mmHg @ 25.00 °C. (est) |
| Flash Point: | 685.00 °F. TCC ( 362.80 °C. ) (est)
|
| logP (o/w): | -0.755 (est) |
| Soluble in: |
| | water, 8228 mg/L @ 25 °C (est) |
Organoleptic Properties:
| |
| Odor and/or flavor descriptions from others (if found). |
| |
| |
Cosmetic Information:
Suppliers:
Safety Information:
| Preferred SDS: View |
| |
| Hazards identification |
| |
| Classification of the substance or mixture |
| GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) |
| None found. |
| GHS Label elements, including precautionary statements |
| |
| Pictogram | |
| |
| Hazard statement(s) |
| None found. |
| Precautionary statement(s) |
| None found. |
| Oral/Parenteral Toxicity: |
intravenous-human TDLo 300 ug/kg GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
BEHAVIORAL: ANOREXIA (HUMAN Journal of Infectious Diseases. Vol. 133, Pg. A192, 1976.
intravenous-human TDLo 2 mg/kg BEHAVIORAL: ATAXIA
BRAIN AND COVERINGS: CHANGES IN SURFACE EEG
BEHAVIORAL: TOXIC PSYCHOSIS Journal of Infectious Diseases. Vol. 134, Pg. 75, 1976.
intraperitoneal-mouse LD50 3057 mg/kg Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.
intravenous-mouse LD50 442 mg/kg Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.
oral-mouse LD50 7800 ug/kg "Kirk-Othmer Encyclopedia of Chemical Technology," 3rd ed., Grayson, M., and D. Eckroth, eds. New York, John Wiley & Sons, Inc., 1978Vol. 2, Pg. 962, 1978.
intraperitoneal-rat LD50 1476 mg/kg Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.
intravenous-rat LD50 302 mg/kg Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.
oral-rat LD50 > 5000 mg/kg LIVER: OTHER CHANGES Annals of the New York Academy of Sciences. Vol. 284, Pg. 6, 1977.
|
| Dermal Toxicity: |
subcutaneous-mouse LD50 5086 mg/kg Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.
subcutaneous-rat LD50 8914 mg/kg Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 15, Pg. 688, 1984.
|
| Inhalation Toxicity: |
|
Not determined
|
Safety in Use Information:
| Category: | pharmaceuticals / chemical synthisis |
| Recommendation for vidarabine usage levels up to: | | | not for fragrance use.
|
| |
| Recommendation for vidarabine flavor usage levels up to: |
| | not for flavor use.
|
Safety References:
References:
| | (2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
| NIST Chemistry WebBook: | Search Inchi |
| Pubchem (cid): | 21704 |
| Pubchem (sid): | 134987129 |
Other Information:
Potential Blenders and core components note
Potential Uses:
Occurrence (nature, food, other): note
Synonyms:
| | adenine 9-b-D-arabinofuranoside | | | adenine-9-b-D-arabinofuranoside | | | adenine-b-D-arabinofuranoside | | | adenine, 9-b-D-arabinofuranosyl- | | | adenine, 9b-D-arabinofuranosyl- | | 6- | amino-9-b-D-arabinofuranosylpurine | | (2R,3S,4S,5R)-2-(6- | amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | | (2R,3S,4S,5R)-2-(6- | aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol | | 9-b-D- | arabinofuranosyl-9H-purin-6-amine (9CI) | | 9-b-D- | arabinofuranosyl-9H-purine-6-amine | | 9-b-D- | arabinofuranosyladenine | | 9b-D- | arabinofuranosyladenine | | (+)- | cyclaradine | | | spongoadenosine | | | vidarabin | | | vidarabinum |
Articles:
|